Meeting News CoverageVideo

VIDEO: Khanna discusses safety, efficacy of tocilizumab for systemic sclerosis

LONDON — At the EULAR Annual Congress, Dinesh Khanna, MD, MSc, spoke about the results of an open-label period of the faSScinate trial. The safety and efficacy of tocilizumab was assessed in patients with systemic sclerosis for 48 weeks of an open-label period.

He said that although the open-label data need to be interpreted with caution, the results indicate the efficacy and safety of the placebo-treated patients who switched to open-label tocilizumab (Actemra, Genentech) were similar to results observed in patients randomized to tocilizumab in the double-blind period. Additionally, results during 96 weeks of treatment with tocilizumab suggested there was a maintenance of the clinical response for the modified Rodnan skin score for patients.

 

LONDON — At the EULAR Annual Congress, Dinesh Khanna, MD, MSc, spoke about the results of an open-label period of the faSScinate trial. The safety and efficacy of tocilizumab was assessed in patients with systemic sclerosis for 48 weeks of an open-label period.

He said that although the open-label data need to be interpreted with caution, the results indicate the efficacy and safety of the placebo-treated patients who switched to open-label tocilizumab (Actemra, Genentech) were similar to results observed in patients randomized to tocilizumab in the double-blind period. Additionally, results during 96 weeks of treatment with tocilizumab suggested there was a maintenance of the clinical response for the modified Rodnan skin score for patients.

 

    See more from EULAR Annual Congress